Chardan initiated coverage of Unity Biotechnology (UBX) with a Buy rating and $6 price target The company’s lead candidate UBX1325 is currently being investigated in the Phase 2b ASPIRE trial in treatment-experienced diabetic macular edema patients, with topline data expected in Q1 of 2025, notes the analyst, who bases the firm’s rating and target on the potential of UBX1325 in DME.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UBX: